CompletedNot Applicable

Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients

16 participantsStarted 2017-01-01

Plain-language summary

Selective retina therapy (SRT) selectively disrupts the retinal pigment epithelium (RPE) with minimal damage to the photoreceptors. Previous studies have shown SRT to be effective for resolving SRF, while causing only minimal collateral damage to the retina and vision.However, most patients included in prior studies had chronic CSC (≥3 months symptom duration) and SRT efficacy on acute CSC is not fully known. The current study evaluated short-term treatment outcomes following SRT with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic CSC.

Who can participate

Age range20 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with treatment-naïve idiopathic central serous chorioretinopathy Exclusion Criteria: * age \> 55 years, * Clinical or angiographic features suggestive of choroidal neovascularization * Optical coherence tomography findings suggestive of type 1 neovascularization or polypoidal choroidal vasculopathy (e.g., double layer sign or fibrovascular pigment epithelial detachment). * History of macular laser photocoagulation, photodynamic therapy, or anti-vascular-endothelial growth factor therapy. * History of exogenous corticosteroid treatment for a systemic disease (e.g., Cushing's syndrome or renal disease).

What they're measuring

Subretinal fluid

Timeframe: 3 months after treatment

Trial details

NCT IDNCT03339856

SponsorKim's Eye Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-09-01

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials